Athenex Announces Key Company Activities at San Antonio Breast Cancer Symposium
- Abstract selected for the SABCS press program
- Oral presentation of Oral Paclitaxel and encequidar Phase III results on
- Company to host a Key Opinion Leader webcast event for the investment community
“We look forward to presenting additional data and analyses at SABCS from the pivotal Phase III study of Oral Paclitaxel in metastatic breast cancer,” said Dr.
|Oral Presentation Details:|
|Abstract Title:||Oral Paclitaxel with Encequidar: The first orally administered paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: a Phase III clinical study in metastatic breast cancer.|
|Session:||General Session 6|
|Date and Time:||Friday, December 13, 2019 at 3:15pm CT|
|Location:||Hall 3 / Henry B. Gonzalez Convention Center, San Antonio, Texas|
|For more information, please visit https://www.sabcs.org/Program/Daily-Schedule/Day-4|
Abstracts that have been selected for the press program will only have titles posted to the SABCS website until the embargo lifts on
KOL Webcast Event
Athenex Exhibit Booth
Attendees at SABCS are invited to visit the exhibit booth hosted by Athenex Oncology at the conference (booth #627/629),
The Orascovery platform was initially developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi.
Founded in 2003,
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. These forward-looking statements are typically identified by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; our reliance on third parties for success in certain areas of Athenex’s business; our history of operating losses and need to raise additional capital to continue as a going concern; our ability to integrate CIDAL’s assets into our existing operations; competition; intellectual property risks; risks relating to doing business in
Chief Financial Officer
Corporate Development and Investor Relations
Source: Athenex, Inc.